BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

April 11 (Reuters) - CymaBay Therapeutics Inc:

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018

* SELADELPAR APPEARS SAFE AND WELL TOLERATED

* RESULTS FROM PHASE 2 OF SELADELPAR STUDY REAFFIRM PLANS FOR ADVANCING TO PHASE 3 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: